Breaking News Instant updates and real-time market news.

TRVN

Trevena

$6.03

0.11 (1.86%)

13:03
10/19/16
10/19
13:03
10/19/16
13:03

Meet Trevena: A talk with CEO Maxine Gowen

Trevena (TRVN) is a clinical-stage biopharmaceutical company focused on the development of therapeutics that target G protein coupled receptors, or GPCRs, for the treatment of acute pain. In an exclusive interview with The Fly, the company's CEO Maxine Gowen talked about the company's ongoing clinical trials, upcoming events, market opportunity for its lead drug and much more. Here are some of the highlights: OLICERIDINE TRIALS ON TRACK: Phase 3 trials for the company's primary candidate Oliceridine, or TVR130, for the treatment of moderate to severe acute pain continue to be on track, with top line data still expected in the first quarter of 2017, CEO Gowen said. According to the executive, Trevena believes it will have sufficient data to support a broad label indication for Oliceridine, without the need to do any further trials aside from the ongoing APOLLO studies in bunionectomy and abdominoplasty and the ATHENA multi procedure trial. A bunionectomy is a surgical procedure to remove a bunion, while an abdominoplasty is a cosmetic surgery procedure used to make the abdomen thinner, more commonly known as a "tummy tuck." LESS ADVERSE EFFECTS: Noting that millions of U.S. patients are treated with an intravenous opioid and have to deal with opioid related adverse effects, Gowen explained that Oliceridine was designed specifically to overcome these adverse events. The executive pointed out that Trevena's clinical data, so far, has shown that Oliceridine can deliver a very rapid pain relief at similar levels to morphine, but with fewer opioid related adverse effects, which she believes will improve hospital care for patients. OTHER PRODUCT CANDIDATES: Aside from Oliceridine, Trevena is developing TRV250 for the treatment of episodic migraine and TRV734 for moderate to severe acute and chronic pain. The CEO expects to submit an Investigational New Drug, or IND, application for '250 to the Food and Drug Administration later this year, which should enable the company to start clinical trials next year. Regarding TRV734, Gowen noted that it makes sense to evaluate a potential partnership as the commercialization of the drug for chronic pain is not "an ideal fit" for the company given Trevena's hospital and specialist focus. CAPITAL TO FUND OPERATIONS INTO 2018: The executive told The Fly that the company maintains its prior guidance, estimating to have enough capital to fund operations into 2018, adding that the company does not discuss plans for future financing. "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. A more detailed version of this interview to follow.

  • 22

    Oct

  • 13

    Dec

TRVN Trevena
$6.03

0.11 (1.86%)

03/02/16
WBTH
03/02/16
INITIATION
Target $18
WBTH
Buy
Trevena initiated with a Buy at WallachBeth
WallachBeth analyst Caroline Palomeque started Trevena with a Buy rating and $18 price target. The company's lead candidate Oliceridine for post-operative acute pain may offer patients a treatment option with comparable analgesic efficacy, a faster onset of action and a more favorable safety profile than morphine, Palomeque tells investors in a research note.
03/02/16
03/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chemical Financial (CHFC) initiated with a Strong Buy at Raymond James by analyst David Long, who believes its pending accretive merger with Talmer Bancorp (TLMR) will provide the base for a more profitable company with strengthened growth prospects. 2. Infinity Pharmaceuticals (INFI) initiated with an Outperform at FBR Capital, with analyst Christopher James saying that duvelisib has the potential to be a first-in-class treatment for specific types of blood cancers. 3. Trevena (TRVN) initiated with a Buy at WallachBeth by analyst Caroline Palomeque, who said Oliceridine may offer patients a treatment option with comparable analgesic efficiency, a faster onset of action and a more favorable safety profile than morphine. 4. Aduro Biotech (ADRO) initiated with an Outperform at FBR Capital. 5. LKQ Corp. (LKQ) initiated with a Buy at Sterne Agee CRT. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/29/16
FBRC
03/29/16
INITIATION
Target $16
FBRC
Outperform
Trevena initiated with an Outperform at FBR Capital
FBR Capital analyst Christopher James started Trevena with an Outperform rating and $16 price target.
05/17/16
ROTH
05/17/16
NO CHANGE
Target $14.5
ROTH
Buy
Roth Capital remains a buyer of Trevena
Roth Capital analyst Michael Higgins reiterates a Buy rating and $14.50 price target on Trevena's shares. The analyst says the company announced that its TRV027 failed in Phase 2 and will be discontinuing the program. However, given the relative risk of development between its oliceridine and its TRV027, Higgins is not making any changes to his financial models. Trevena is "well-capitalized," with cash sufficient to fund operations for two years, the analyst tells investors in a research note, adding that he sees the company's shares as being at an "attractive entry point."

TODAY'S FREE FLY STORIES

DAL

Delta Air Lines

$52.94

0.02 (0.04%)

13:26
06/26/17
06/26
13:26
06/26/17
13:26
Periodicals
Amtrak picks former Delta CEO Anderson as new CEO, WSJ reports »

Former Delta CEO Richard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 30

    Jun

  • 07

    Jul

13:25
06/26/17
06/26
13:25
06/26/17
13:25
General news
Treasury Action: shorter yields dipped slightly after the strong 2-year sale »

Treasury Action: shorter…

PDCE

PDC Energy

$44.72

2.21 (5.20%)

13:22
06/26/17
06/26
13:22
06/26/17
13:22
Hot Stocks
Department of Justice, Colorado file civil complaint against PDC Energy »

The Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

13:20
06/26/17
06/26
13:20
06/26/17
13:20
Options
Call buyer opens a notable new position in 20th Century Fox »

Call buyer opens a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$155.07

1.67 (1.09%)

, MSFT

Microsoft

$71.21

0.95 (1.35%)

13:19
06/26/17
06/26
13:19
06/26/17
13:19
Hot Stocks
Facebook, Twitter, Microsoft, YouTube form global forum to counter terrorism »

Facebook (FB), Microsoft…

FB

Facebook

$155.07

1.67 (1.09%)

MSFT

Microsoft

$71.21

0.95 (1.35%)

TWTR

Twitter

$18.35

-0.155 (-0.84%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

  • 20

    Jul

$NSD

NASDAQ Market Internals

13:17
06/26/17
06/26
13:17
06/26/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
06/26/17
06/26
13:16
06/26/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$56.22

-0.08 (-0.14%)

, SPY

SPDR S&P 500 ETF Trust

$243.72

0.59 (0.24%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Technical Analysis
Technical View: S&P 500 chart view at mid-session »

The small bearish price…

XLK

Technology Select Sector SPDR

$56.22

-0.08 (-0.14%)

SPY

SPDR S&P 500 ETF Trust

$243.72

0.59 (0.24%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GG

Goldcorp

$13.68

-0.12 (-0.87%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Options
Goldcorp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

KR

Kroger

$22.58

-0.02 (-0.09%)

13:15
06/26/17
06/26
13:15
06/26/17
13:15
Hot Stocks
Kroger executive VP Schlotman acquires 2,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
06/26/17
06/26
13:15
06/26/17
13:15
General news
Treasury's $26 B 2-year sale was well received, as expected »

Treasury's $26 B…

DB

Deutsche Bank

$16.89

0.25 (1.50%)

13:12
06/26/17
06/26
13:12
06/26/17
13:12
Periodicals
Deutsche Bank's chief U.S. economist LaVorgna steps down, Bloomberg reports »

Joe LaVorgna, a chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

WDC

Western Digital

$93.34

3.09 (3.42%)

, TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

13:11
06/26/17
06/26
13:11
06/26/17
13:11
Periodicals
Toshiba near sale of memory chip unit to consortium, Nikkei reports »

Toshiba (TOSYY) could…

WDC

Western Digital

$93.34

3.09 (3.42%)

TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

TOSBF

Toshiba, also use TOSYY

$2.66

-0.22 (-7.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$146.28

0.65 (0.45%)

13:09
06/26/17
06/26
13:09
06/26/17
13:09
Hot Stocks
Apple CEO: 'Inspired' by Indian PM Modi's vision »

Following a meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ZIXI

ZixCorp

$5.77

-0.06 (-1.03%)

13:05
06/26/17
06/26
13:05
06/26/17
13:05
Hot Stocks
Breaking Hot Stocks news story on ZixCorp »

ETF Managers reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$28.97

-0.29 (-0.99%)

12:58
06/26/17
06/26
12:58
06/26/17
12:58
Hot Stocks
Breaking Hot Stocks news story on Reata Pharmaceuticals »

Novo Holdings cuts Reata…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

HSTM

HealthStream

$30.89

0.72 (2.39%)

12:57
06/26/17
06/26
12:57
06/26/17
12:57
Recommendations
HealthStream analyst commentary  »

HealthStream contract end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

12:55
06/26/17
06/26
12:55
06/26/17
12:55
General news
Treasury 2-year auction preview: the sale should see decent results »

Treasury 2-year auction…

12:55
06/26/17
06/26
12:55
06/26/17
12:55
General news
Breaking General news story  »

San Francisco Federal…

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

12:46
06/26/17
06/26
12:46
06/26/17
12:46
Hot Stocks
Amazon CEO: Excited to keep investing in India »

Following a meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

  • 28

    Jun

GOOG

Alphabet

$965.59

8.5 (0.89%)

, GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

12:43
06/26/17
06/26
12:43
06/26/17
12:43
Periodicals
EU to likely hit Google with record fine in antitrust case, Reuters says »

EU antitrust authorities…

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

NURO

NeuroMetrix

$2.95

0.06 (2.08%)

12:39
06/26/17
06/26
12:39
06/26/17
12:39
Hot Stocks
NeuroMetrix names Xuan Kong as Chief Data Scientist »

NeuroMetrix provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$17.41

-0.13 (-0.74%)

12:38
06/26/17
06/26
12:38
06/26/17
12:38
Periodicals
Snap taps Internet Association's Woodworth for public policy team, Recode says »

Recode's Tony Romm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 19

    Jul

DEO

Diageo

$120.05

0.7915 (0.66%)

12:36
06/26/17
06/26
12:36
06/26/17
12:36
Upgrade
Diageo rating change  »

Diageo upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOSBF

Toshiba, also use TOSYY

$2.66

-0.22 (-7.64%)

, TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

12:36
06/26/17
06/26
12:36
06/26/17
12:36
Periodicals
Two bidders remain in Toshiba's Landis+Gyr auction, Reuters reports »

The group of prospective…

TOSBF

Toshiba, also use TOSYY

$2.66

-0.22 (-7.64%)

TOSYY

Toshiba, also use TOSBF

$15.98

-1.415 (-8.14%)

GS

Goldman Sachs

$219.98

2.79 (1.28%)

ONEXF

Onex

$77.08

1.32 (1.74%)

HTHIY

Hitachi

$60.70

0.32 (0.53%)

HON

Honeywell

$134.27

0.28 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 21

    Jul

  • 26

    Jul

  • 30

    Jul

  • 17

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.